Published On: Wed, Sep 13th, 2017

Reviewing Individual Broker Targets Of TriVascular Technologies, Inc. (NASDAQ:TRIV)


Recently stock market analysts have updated their consensus ratings on shares of TriVascular Technologies, Inc. (NASDAQ:TRIV).

Most recent broker ratings

11/23/2015 – TriVascular Technologies, Inc. was downgraded to “neutral” by analysts at BTIG Research.

08/10/2015 – TriVascular Technologies, Inc. had its “hold” rating reiterated by analysts at Credit Suisse. They now have a USD 8 price target on the stock.

08/05/2015 – TriVascular Technologies, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 13 price target on the stock.

05/08/2015 – TriVascular Technologies, Inc. was downgraded to “sell” by analysts at Zacks.

05/06/2015 – TriVascular Technologies, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 11 price target on the stock.

05/06/2015 – TriVascular Technologies, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 9 price target on the stock.

TriVascular Technologies, Inc. has a 50 day moving average of 6.49 and a 200 day moving average of 6.07.It has a 52-week low of 3.98 and a 52-week high of 11.49.

The share price of the company (NASDAQ:TRIV) was up +0.00% during the last trading session, with a high of 0.00 and the volume of TriVascular Technologies, Inc. shares traded was 0.

Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.